188 related articles for article (PubMed ID: 9753473)
1. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.
Ridky TW; Kikonyogo A; Leis J; Gulnik S; Copeland T; Erickson J; Wlodawer A; Kurinov I; Harrison RW; Weber IT
Biochemistry; 1998 Sep; 37(39):13835-45. PubMed ID: 9753473
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases.
Cameron CE; Ridky TW; Shulenin S; Leis J; Weber IT; Copeland T; Wlodawer A; Burstein H; Bizub-Bender D; Skalka AM
J Biol Chem; 1994 Apr; 269(15):11170-7. PubMed ID: 8157644
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for specificity of retroviral proteases.
Wu J; Adomat JM; Ridky TW; Louis JM; Leis J; Harrison RW; Weber IT
Biochemistry; 1998 Mar; 37(13):4518-26. PubMed ID: 9521772
[TBL] [Abstract][Full Text] [Related]
4. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
5. Combining mutations in HIV-1 protease to understand mechanisms of resistance.
Mahalingam B; Boross P; Wang YF; Louis JM; Fischer CC; Tozser J; Harrison RW; Weber IT
Proteins; 2002 Jul; 48(1):107-16. PubMed ID: 12012342
[TBL] [Abstract][Full Text] [Related]
6. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates.
Grinde B; Cameron CE; Leis J; Weber IT; Wlodawer A; Burstein H; Skalka AM
J Biol Chem; 1992 May; 267(14):9491-8. PubMed ID: 1315756
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Hong L; Zhang XC; Hartsuck JA; Tang J
Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
11. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
Fehér A; Weber IT; Bagossi P; Boross P; Mahalingam B; Louis JM; Copeland TD; Torshin IY; Harrison RW; Tözsér J
Eur J Biochem; 2002 Aug; 269(16):4114-20. PubMed ID: 12180988
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
[TBL] [Abstract][Full Text] [Related]
13. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
Todd MJ; Luque I; Velázquez-Campoy A; Freire E
Biochemistry; 2000 Oct; 39(39):11876-83. PubMed ID: 11009599
[TBL] [Abstract][Full Text] [Related]
14. Programming the Rous sarcoma virus protease to cleave new substrate sequences.
Ridky TW; Bizub-Bender D; Cameron CE; Weber IT; Wlodawer A; Copeland T; Skalka AM; Leis J
J Biol Chem; 1996 May; 271(18):10538-44. PubMed ID: 8631853
[TBL] [Abstract][Full Text] [Related]
15. Mutations that alter the activity of the Rous sarcoma virus protease.
Grinde B; Cameron CE; Leis J; Weber IT; Wlodawer A; Burstein H; Bizub D; Skalka AM
J Biol Chem; 1992 May; 267(14):9481-90. PubMed ID: 1315755
[TBL] [Abstract][Full Text] [Related]
16. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
Rose RB; Craik CS; Stroud RM
Biochemistry; 1998 Feb; 37(8):2607-21. PubMed ID: 9485411
[TBL] [Abstract][Full Text] [Related]
17. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
[TBL] [Abstract][Full Text] [Related]
19. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
20. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
